Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Increases By 15.4%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totalling 1,500 shares, an increase of 15.4% from the May 31st total of 1,300 shares. Based on an average trading volume of 300 shares, the days-to-cover ratio is currently 5.0 days.

Inhibitor Therapeutics Price Performance

Shares of INTI opened at $0.08 on Monday. The firm’s 50 day moving average price is $0.09 and its 200 day moving average price is $0.08. Inhibitor Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.30.

Inhibitor Therapeutics (OTCMKTS:INTI) last issued its quarterly earnings data on Friday, March 29th. The company reported ($0.01) earnings per share for the quarter.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.